Consumer Education, Cost Reductions, and Inter-Industry Alliances Seen as Vital for U.S. EV OEMs Eyeing Global Market Domination

Indy Autonomous Challenge Banner Ad

 

In the wake of a global push towards sustainable transportation, the United States finds itself at a critical juncture in the electric vehicle (EV) industry. With increasing pressure to compete internationally, the need to educate consumers on the benefits of EV adoption and foster inter-industry and public-private alliances on best manufacturing practices has never been more urgent. As U.S. EV Original Equipment Manufacturers (OEMs) strive to carve out their place in the global market, strategic initiatives become paramount to success.

How can educating consumers on EV benefits and fostering inter-industry alliances enhance the competitiveness of U.S. EV OEMs on the international stage?

On a riveting episode of Expert’s Talk, Michael Davies, the Founder & Data Scientist at Green Econometrics, offers invaluable insights into the strategies essential for bolstering U.S. EV competitiveness in the global market. Drawing from his extensive expertise, Davies advocates for consumer education as a means to alleviate concerns surrounding EV adoption while emphasizing the imperative of inter-industry alliances to drive down manufacturing costs and enhance market presence.

Key Insights: 

  • Educating the Consumer: Davies emphasizes the importance of educating consumers on the benefits of EV adoption, highlighting the need to address concerns such as infrastructure challenges.
  • Cost Reduction: Lowering vehicle prices is crucial to penetrating the mass market, thereby achieving the necessary volume to reduce operating costs.
  • Inter-Industry Alliances: Davies stresses the necessity of alliances between government entities and industry stakeholders to share best manufacturing practices and foster competitiveness.
  • Global Market Dynamics: The expert underscores the significance of global market trends, citing China’s proactive approach and Europe’s emulation, warning against complacency in the face of international competition.
  • Risk of Inaction: Davies warns that without concerted efforts to innovate and adapt, the U.S. risks ceding its position in the automotive industry.

Article written by Sonia Gossai

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More